Ajanta Pharma Limited

AJANTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AJANTPHARM.NS stands at 372.2B. In comparison, SUNPHARMA.NS has a market cap of 4.3T. Regarding current trading prices, AJANTPHARM.NS is priced at ₹2,978.90, while SUNPHARMA.NS trades at ₹1,785.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AJANTPHARM.NS currently has a P/E ratio of 36.65, whereas SUNPHARMA.NS's P/E ratio is 39.19. In terms of profitability, AJANTPHARM.NS's ROE is +0.26%, compared to SUNPHARMA.NS's ROE of +0.15%. Regarding short-term risk, AJANTPHARM.NS is more volatile compared to SUNPHARMA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AJANTPHARM.NS.Check SUNPHARMA.NS's competition here

AJANTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AJANTPHARM.NS stands at 372.2B. In comparison, SUNPHARMA.BO has a market cap of 4.3T. Regarding current trading prices, AJANTPHARM.NS is priced at ₹2,978.90, while SUNPHARMA.BO trades at ₹1,784.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AJANTPHARM.NS currently has a P/E ratio of 36.65, whereas SUNPHARMA.BO's P/E ratio is 39.22. In terms of profitability, AJANTPHARM.NS's ROE is +0.26%, compared to SUNPHARMA.BO's ROE of +0.15%. Regarding short-term risk, AJANTPHARM.NS is more volatile compared to SUNPHARMA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AJANTPHARM.NS.Check SUNPHARMA.BO's competition here

AJANTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AJANTPHARM.NS stands at 372.2B. In comparison, DIVISLAB.NS has a market cap of 1.7T. Regarding current trading prices, AJANTPHARM.NS is priced at ₹2,978.90, while DIVISLAB.NS trades at ₹6,474.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AJANTPHARM.NS currently has a P/E ratio of 36.65, whereas DIVISLAB.NS's P/E ratio is 69.34. In terms of profitability, AJANTPHARM.NS's ROE is +0.26%, compared to DIVISLAB.NS's ROE of +0.17%. Regarding short-term risk, AJANTPHARM.NS is less volatile compared to DIVISLAB.NS. This indicates potentially lower risk in terms of short-term price fluctuations for AJANTPHARM.NS.Check DIVISLAB.NS's competition here

AJANTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AJANTPHARM.NS stands at 372.2B. In comparison, DIVISLAB.BO has a market cap of 1.7T. Regarding current trading prices, AJANTPHARM.NS is priced at ₹2,978.90, while DIVISLAB.BO trades at ₹6,470.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AJANTPHARM.NS currently has a P/E ratio of 36.65, whereas DIVISLAB.BO's P/E ratio is 69.27. In terms of profitability, AJANTPHARM.NS's ROE is +0.26%, compared to DIVISLAB.BO's ROE of +0.17%. Regarding short-term risk, AJANTPHARM.NS is less volatile compared to DIVISLAB.BO. This indicates potentially lower risk in terms of short-term price fluctuations for AJANTPHARM.NS.Check DIVISLAB.BO's competition here

AJANTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AJANTPHARM.NS stands at 372.2B. In comparison, TORNTPHARM.BO has a market cap of 1.5T. Regarding current trading prices, AJANTPHARM.NS is priced at ₹2,978.90, while TORNTPHARM.BO trades at ₹4,400.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AJANTPHARM.NS currently has a P/E ratio of 36.65, whereas TORNTPHARM.BO's P/E ratio is 69.57. In terms of profitability, AJANTPHARM.NS's ROE is +0.26%, compared to TORNTPHARM.BO's ROE of +0.29%. Regarding short-term risk, AJANTPHARM.NS is more volatile compared to TORNTPHARM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AJANTPHARM.NS.Check TORNTPHARM.BO's competition here

AJANTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AJANTPHARM.NS stands at 372.2B. In comparison, TORNTPHARM.NS has a market cap of 1.5T. Regarding current trading prices, AJANTPHARM.NS is priced at ₹2,978.90, while TORNTPHARM.NS trades at ₹4,399.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AJANTPHARM.NS currently has a P/E ratio of 36.65, whereas TORNTPHARM.NS's P/E ratio is 65.47. In terms of profitability, AJANTPHARM.NS's ROE is +0.26%, compared to TORNTPHARM.NS's ROE of +0.29%. Regarding short-term risk, AJANTPHARM.NS is more volatile compared to TORNTPHARM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AJANTPHARM.NS.Check TORNTPHARM.NS's competition here

AJANTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AJANTPHARM.NS stands at 372.2B. In comparison, DRREDDY.NS has a market cap of 1.1T. Regarding current trading prices, AJANTPHARM.NS is priced at ₹2,978.90, while DRREDDY.NS trades at ₹1,319.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AJANTPHARM.NS currently has a P/E ratio of 36.65, whereas DRREDDY.NS's P/E ratio is 19.44. In terms of profitability, AJANTPHARM.NS's ROE is +0.26%, compared to DRREDDY.NS's ROE of +0.16%. Regarding short-term risk, AJANTPHARM.NS is more volatile compared to DRREDDY.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AJANTPHARM.NS.Check DRREDDY.NS's competition here

AJANTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AJANTPHARM.NS stands at 372.2B. In comparison, DRREDDY.BO has a market cap of 1.1T. Regarding current trading prices, AJANTPHARM.NS is priced at ₹2,978.90, while DRREDDY.BO trades at ₹1,318.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AJANTPHARM.NS currently has a P/E ratio of 36.65, whereas DRREDDY.BO's P/E ratio is 19.44. In terms of profitability, AJANTPHARM.NS's ROE is +0.26%, compared to DRREDDY.BO's ROE of +0.16%. Regarding short-term risk, AJANTPHARM.NS is more volatile compared to DRREDDY.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AJANTPHARM.NS.Check DRREDDY.BO's competition here

AJANTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AJANTPHARM.NS stands at 372.2B. In comparison, LUPIN.NS has a market cap of 1.1T. Regarding current trading prices, AJANTPHARM.NS is priced at ₹2,978.90, while LUPIN.NS trades at ₹2,323.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AJANTPHARM.NS currently has a P/E ratio of 36.65, whereas LUPIN.NS's P/E ratio is 22.89. In terms of profitability, AJANTPHARM.NS's ROE is +0.26%, compared to LUPIN.NS's ROE of +0.27%. Regarding short-term risk, AJANTPHARM.NS is more volatile compared to LUPIN.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AJANTPHARM.NS.Check LUPIN.NS's competition here

AJANTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AJANTPHARM.NS stands at 372.2B. In comparison, LUPIN.BO has a market cap of 1.1T. Regarding current trading prices, AJANTPHARM.NS is priced at ₹2,978.90, while LUPIN.BO trades at ₹2,323.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AJANTPHARM.NS currently has a P/E ratio of 36.65, whereas LUPIN.BO's P/E ratio is 24.62. In terms of profitability, AJANTPHARM.NS's ROE is +0.26%, compared to LUPIN.BO's ROE of +0.27%. Regarding short-term risk, AJANTPHARM.NS is more volatile compared to LUPIN.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AJANTPHARM.NS.Check LUPIN.BO's competition here

AJANTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AJANTPHARM.NS stands at 372.2B. In comparison, ZYDUSLIFE.NS has a market cap of 944.4B. Regarding current trading prices, AJANTPHARM.NS is priced at ₹2,978.90, while ZYDUSLIFE.NS trades at ₹938.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AJANTPHARM.NS currently has a P/E ratio of 36.65, whereas ZYDUSLIFE.NS's P/E ratio is 19.11. In terms of profitability, AJANTPHARM.NS's ROE is +0.26%, compared to ZYDUSLIFE.NS's ROE of +0.20%. Regarding short-term risk, AJANTPHARM.NS is more volatile compared to ZYDUSLIFE.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AJANTPHARM.NS.Check ZYDUSLIFE.NS's competition here

AJANTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AJANTPHARM.NS stands at 372.2B. In comparison, ZYDUSLIFE.BO has a market cap of 944B. Regarding current trading prices, AJANTPHARM.NS is priced at ₹2,978.90, while ZYDUSLIFE.BO trades at ₹938.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AJANTPHARM.NS currently has a P/E ratio of 36.65, whereas ZYDUSLIFE.BO's P/E ratio is 19.11. In terms of profitability, AJANTPHARM.NS's ROE is +0.26%, compared to ZYDUSLIFE.BO's ROE of +0.20%. Regarding short-term risk, AJANTPHARM.NS is more volatile compared to ZYDUSLIFE.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AJANTPHARM.NS.Check ZYDUSLIFE.BO's competition here

AJANTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AJANTPHARM.NS stands at 372.2B. In comparison, MANKIND.BO has a market cap of 941.2B. Regarding current trading prices, AJANTPHARM.NS is priced at ₹2,978.90, while MANKIND.BO trades at ₹2,280.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AJANTPHARM.NS currently has a P/E ratio of 36.65, whereas MANKIND.BO's P/E ratio is 52.82. In terms of profitability, AJANTPHARM.NS's ROE is +0.26%, compared to MANKIND.BO's ROE of +0.13%. Regarding short-term risk, AJANTPHARM.NS is less volatile compared to MANKIND.BO. This indicates potentially lower risk in terms of short-term price fluctuations for AJANTPHARM.NS.Check MANKIND.BO's competition here

AJANTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AJANTPHARM.NS stands at 372.2B. In comparison, MANKIND.NS has a market cap of 941.1B. Regarding current trading prices, AJANTPHARM.NS is priced at ₹2,978.90, while MANKIND.NS trades at ₹2,279.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AJANTPHARM.NS currently has a P/E ratio of 36.65, whereas MANKIND.NS's P/E ratio is 52.80. In terms of profitability, AJANTPHARM.NS's ROE is +0.26%, compared to MANKIND.NS's ROE of +0.13%. Regarding short-term risk, AJANTPHARM.NS is less volatile compared to MANKIND.NS. This indicates potentially lower risk in terms of short-term price fluctuations for AJANTPHARM.NS.Check MANKIND.NS's competition here

AJANTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AJANTPHARM.NS stands at 372.2B. In comparison, AUROPHARMA.BO has a market cap of 709.7B. Regarding current trading prices, AJANTPHARM.NS is priced at ₹2,978.90, while AUROPHARMA.BO trades at ₹1,222.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AJANTPHARM.NS currently has a P/E ratio of 36.65, whereas AUROPHARMA.BO's P/E ratio is 20.75. In terms of profitability, AJANTPHARM.NS's ROE is +0.26%, compared to AUROPHARMA.BO's ROE of +0.11%. Regarding short-term risk, AJANTPHARM.NS is less volatile compared to AUROPHARMA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for AJANTPHARM.NS.Check AUROPHARMA.BO's competition here

AJANTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AJANTPHARM.NS stands at 372.2B. In comparison, AUROPHARMA.NS has a market cap of 709B. Regarding current trading prices, AJANTPHARM.NS is priced at ₹2,978.90, while AUROPHARMA.NS trades at ₹1,220.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AJANTPHARM.NS currently has a P/E ratio of 36.65, whereas AUROPHARMA.NS's P/E ratio is 20.32. In terms of profitability, AJANTPHARM.NS's ROE is +0.26%, compared to AUROPHARMA.NS's ROE of +0.11%. Regarding short-term risk, AJANTPHARM.NS is less volatile compared to AUROPHARMA.NS. This indicates potentially lower risk in terms of short-term price fluctuations for AJANTPHARM.NS.Check AUROPHARMA.NS's competition here

AJANTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AJANTPHARM.NS stands at 372.2B. In comparison, ALKEM.NS has a market cap of 687.7B. Regarding current trading prices, AJANTPHARM.NS is priced at ₹2,978.90, while ALKEM.NS trades at ₹5,752.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AJANTPHARM.NS currently has a P/E ratio of 36.65, whereas ALKEM.NS's P/E ratio is 28.97. In terms of profitability, AJANTPHARM.NS's ROE is +0.26%, compared to ALKEM.NS's ROE of +0.19%. Regarding short-term risk, AJANTPHARM.NS is more volatile compared to ALKEM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AJANTPHARM.NS.Check ALKEM.NS's competition here

AJANTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AJANTPHARM.NS stands at 372.2B. In comparison, ALKEM.BO has a market cap of 687.6B. Regarding current trading prices, AJANTPHARM.NS is priced at ₹2,978.90, while ALKEM.BO trades at ₹5,750.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AJANTPHARM.NS currently has a P/E ratio of 36.65, whereas ALKEM.BO's P/E ratio is 29.00. In terms of profitability, AJANTPHARM.NS's ROE is +0.26%, compared to ALKEM.BO's ROE of +0.19%. Regarding short-term risk, AJANTPHARM.NS is more volatile compared to ALKEM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AJANTPHARM.NS.Check ALKEM.BO's competition here

AJANTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AJANTPHARM.NS stands at 372.2B. In comparison, GLENMARK.BO has a market cap of 600.3B. Regarding current trading prices, AJANTPHARM.NS is priced at ₹2,978.90, while GLENMARK.BO trades at ₹2,127.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AJANTPHARM.NS currently has a P/E ratio of 36.65, whereas GLENMARK.BO's P/E ratio is 56.38. In terms of profitability, AJANTPHARM.NS's ROE is +0.26%, compared to GLENMARK.BO's ROE of +0.12%. Regarding short-term risk, AJANTPHARM.NS is more volatile compared to GLENMARK.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AJANTPHARM.NS.Check GLENMARK.BO's competition here

AJANTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AJANTPHARM.NS stands at 372.2B. In comparison, GLENMARK.NS has a market cap of 599.5B. Regarding current trading prices, AJANTPHARM.NS is priced at ₹2,978.90, while GLENMARK.NS trades at ₹2,124.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AJANTPHARM.NS currently has a P/E ratio of 36.65, whereas GLENMARK.NS's P/E ratio is 56.39. In terms of profitability, AJANTPHARM.NS's ROE is +0.26%, compared to GLENMARK.NS's ROE of +0.12%. Regarding short-term risk, AJANTPHARM.NS is less volatile compared to GLENMARK.NS. This indicates potentially lower risk in terms of short-term price fluctuations for AJANTPHARM.NS.Check GLENMARK.NS's competition here

AJANTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AJANTPHARM.NS stands at 372.2B. In comparison, LAURUSLABS.NS has a market cap of 589.9B. Regarding current trading prices, AJANTPHARM.NS is priced at ₹2,978.90, while LAURUSLABS.NS trades at ₹1,092.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AJANTPHARM.NS currently has a P/E ratio of 36.65, whereas LAURUSLABS.NS's P/E ratio is 69.91. In terms of profitability, AJANTPHARM.NS's ROE is +0.26%, compared to LAURUSLABS.NS's ROE of +0.19%. Regarding short-term risk, AJANTPHARM.NS is less volatile compared to LAURUSLABS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for AJANTPHARM.NS.Check LAURUSLABS.NS's competition here

AJANTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AJANTPHARM.NS stands at 372.2B. In comparison, LAURUSLABS.BO has a market cap of 589.8B. Regarding current trading prices, AJANTPHARM.NS is priced at ₹2,978.90, while LAURUSLABS.BO trades at ₹1,092.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AJANTPHARM.NS currently has a P/E ratio of 36.65, whereas LAURUSLABS.BO's P/E ratio is 69.81. In terms of profitability, AJANTPHARM.NS's ROE is +0.26%, compared to LAURUSLABS.BO's ROE of +0.19%. Regarding short-term risk, AJANTPHARM.NS is more volatile compared to LAURUSLABS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AJANTPHARM.NS.Check LAURUSLABS.BO's competition here

AJANTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AJANTPHARM.NS stands at 372.2B. In comparison, SUVENPHAR.NS has a market cap of 412.4B. Regarding current trading prices, AJANTPHARM.NS is priced at ₹2,978.90, while SUVENPHAR.NS trades at ₹1,078.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AJANTPHARM.NS currently has a P/E ratio of 36.65, whereas SUVENPHAR.NS's P/E ratio is 98.90. In terms of profitability, AJANTPHARM.NS's ROE is +0.26%, compared to SUVENPHAR.NS's ROE of +0.13%. Regarding short-term risk, AJANTPHARM.NS is less volatile compared to SUVENPHAR.NS. This indicates potentially lower risk in terms of short-term price fluctuations for AJANTPHARM.NS.Check SUVENPHAR.NS's competition here

AJANTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AJANTPHARM.NS stands at 372.2B. In comparison, SUVENPHAR.BO has a market cap of 411.4B. Regarding current trading prices, AJANTPHARM.NS is priced at ₹2,978.90, while SUVENPHAR.BO trades at ₹1,075.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AJANTPHARM.NS currently has a P/E ratio of 36.65, whereas SUVENPHAR.BO's P/E ratio is 98.29. In terms of profitability, AJANTPHARM.NS's ROE is +0.26%, compared to SUVENPHAR.BO's ROE of +0.09%. Regarding short-term risk, AJANTPHARM.NS is less volatile compared to SUVENPHAR.BO. This indicates potentially lower risk in terms of short-term price fluctuations for AJANTPHARM.NS.Check SUVENPHAR.BO's competition here

AJANTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AJANTPHARM.NS stands at 372.2B. In comparison, IPCALAB.NS has a market cap of 386.3B. Regarding current trading prices, AJANTPHARM.NS is priced at ₹2,978.90, while IPCALAB.NS trades at ₹1,522.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AJANTPHARM.NS currently has a P/E ratio of 36.65, whereas IPCALAB.NS's P/E ratio is 42.52. In terms of profitability, AJANTPHARM.NS's ROE is +0.26%, compared to IPCALAB.NS's ROE of +0.12%. Regarding short-term risk, AJANTPHARM.NS is less volatile compared to IPCALAB.NS. This indicates potentially lower risk in terms of short-term price fluctuations for AJANTPHARM.NS.Check IPCALAB.NS's competition here

AJANTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AJANTPHARM.NS stands at 372.2B. In comparison, IPCALAB.BO has a market cap of 386.3B. Regarding current trading prices, AJANTPHARM.NS is priced at ₹2,978.90, while IPCALAB.BO trades at ₹1,522.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AJANTPHARM.NS currently has a P/E ratio of 36.65, whereas IPCALAB.BO's P/E ratio is 42.43. In terms of profitability, AJANTPHARM.NS's ROE is +0.26%, compared to IPCALAB.BO's ROE of +0.12%. Regarding short-term risk, AJANTPHARM.NS is less volatile compared to IPCALAB.BO. This indicates potentially lower risk in terms of short-term price fluctuations for AJANTPHARM.NS.Check IPCALAB.BO's competition here

AJANTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AJANTPHARM.NS stands at 372.2B. In comparison, AJANTPHARM.BO has a market cap of 372.5B. Regarding current trading prices, AJANTPHARM.NS is priced at ₹2,978.90, while AJANTPHARM.BO trades at ₹2,981.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AJANTPHARM.NS currently has a P/E ratio of 36.65, whereas AJANTPHARM.BO's P/E ratio is 36.76. In terms of profitability, AJANTPHARM.NS's ROE is +0.26%, compared to AJANTPHARM.BO's ROE of +0.26%. Regarding short-term risk, AJANTPHARM.NS is more volatile compared to AJANTPHARM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AJANTPHARM.NS.Check AJANTPHARM.BO's competition here

AJANTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AJANTPHARM.NS stands at 372.2B. In comparison, JBCHEPHARM.BO has a market cap of 334.4B. Regarding current trading prices, AJANTPHARM.NS is priced at ₹2,978.90, while JBCHEPHARM.BO trades at ₹2,082.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AJANTPHARM.NS currently has a P/E ratio of 36.65, whereas JBCHEPHARM.BO's P/E ratio is 43.95. In terms of profitability, AJANTPHARM.NS's ROE is +0.26%, compared to JBCHEPHARM.BO's ROE of +0.22%. Regarding short-term risk, AJANTPHARM.NS is more volatile compared to JBCHEPHARM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AJANTPHARM.NS.Check JBCHEPHARM.BO's competition here

AJANTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AJANTPHARM.NS stands at 372.2B. In comparison, JBCHEPHARM.NS has a market cap of 334.1B. Regarding current trading prices, AJANTPHARM.NS is priced at ₹2,978.90, while JBCHEPHARM.NS trades at ₹2,081.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AJANTPHARM.NS currently has a P/E ratio of 36.65, whereas JBCHEPHARM.NS's P/E ratio is 43.90. In terms of profitability, AJANTPHARM.NS's ROE is +0.26%, compared to JBCHEPHARM.NS's ROE of +0.22%. Regarding short-term risk, AJANTPHARM.NS is more volatile compared to JBCHEPHARM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AJANTPHARM.NS.Check JBCHEPHARM.NS's competition here

AJANTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AJANTPHARM.NS stands at 372.2B. In comparison, EMCURE.NS has a market cap of 275.7B. Regarding current trading prices, AJANTPHARM.NS is priced at ₹2,978.90, while EMCURE.NS trades at ₹1,454.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AJANTPHARM.NS currently has a P/E ratio of 36.65, whereas EMCURE.NS's P/E ratio is 31.69. In terms of profitability, AJANTPHARM.NS's ROE is +0.26%, compared to EMCURE.NS's ROE of +0.20%. Regarding short-term risk, AJANTPHARM.NS is less volatile compared to EMCURE.NS. This indicates potentially lower risk in terms of short-term price fluctuations for AJANTPHARM.NS.Check EMCURE.NS's competition here

AJANTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AJANTPHARM.NS stands at 372.2B. In comparison, PEL.NS has a market cap of 254.9B. Regarding current trading prices, AJANTPHARM.NS is priced at ₹2,978.90, while PEL.NS trades at ₹1,124.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AJANTPHARM.NS currently has a P/E ratio of 36.65, whereas PEL.NS's P/E ratio is 44.24. In terms of profitability, AJANTPHARM.NS's ROE is +0.26%, compared to PEL.NS's ROE of +0.02%. Regarding short-term risk, AJANTPHARM.NS is less volatile compared to PEL.NS. This indicates potentially lower risk in terms of short-term price fluctuations for AJANTPHARM.NS.Check PEL.NS's competition here

AJANTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AJANTPHARM.NS stands at 372.2B. In comparison, WOCKPHARMA.BO has a market cap of 221.8B. Regarding current trading prices, AJANTPHARM.NS is priced at ₹2,978.90, while WOCKPHARMA.BO trades at ₹1,365.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AJANTPHARM.NS currently has a P/E ratio of 36.65, whereas WOCKPHARMA.BO's P/E ratio is 1109.96. In terms of profitability, AJANTPHARM.NS's ROE is +0.26%, compared to WOCKPHARMA.BO's ROE of +0.01%. Regarding short-term risk, AJANTPHARM.NS is less volatile compared to WOCKPHARMA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for AJANTPHARM.NS.Check WOCKPHARMA.BO's competition here

AJANTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AJANTPHARM.NS stands at 372.2B. In comparison, WOCKPHARMA.NS has a market cap of 221.6B. Regarding current trading prices, AJANTPHARM.NS is priced at ₹2,978.90, while WOCKPHARMA.NS trades at ₹1,363.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AJANTPHARM.NS currently has a P/E ratio of 36.65, whereas WOCKPHARMA.NS's P/E ratio is 1108.62. In terms of profitability, AJANTPHARM.NS's ROE is +0.26%, compared to WOCKPHARMA.NS's ROE of +0.01%. Regarding short-term risk, AJANTPHARM.NS is less volatile compared to WOCKPHARMA.NS. This indicates potentially lower risk in terms of short-term price fluctuations for AJANTPHARM.NS.Check WOCKPHARMA.NS's competition here

AJANTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AJANTPHARM.NS stands at 372.2B. In comparison, ASTRAZEN.BO has a market cap of 221.3B. Regarding current trading prices, AJANTPHARM.NS is priced at ₹2,978.90, while ASTRAZEN.BO trades at ₹8,850.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AJANTPHARM.NS currently has a P/E ratio of 36.65, whereas ASTRAZEN.BO's P/E ratio is 110.63. In terms of profitability, AJANTPHARM.NS's ROE is +0.26%, compared to ASTRAZEN.BO's ROE of +0.27%. Regarding short-term risk, AJANTPHARM.NS is more volatile compared to ASTRAZEN.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AJANTPHARM.NS.Check ASTRAZEN.BO's competition here

AJANTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AJANTPHARM.NS stands at 372.2B. In comparison, ASTRAZEN.NS has a market cap of 221.2B. Regarding current trading prices, AJANTPHARM.NS is priced at ₹2,978.90, while ASTRAZEN.NS trades at ₹8,849.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AJANTPHARM.NS currently has a P/E ratio of 36.65, whereas ASTRAZEN.NS's P/E ratio is 110.50. In terms of profitability, AJANTPHARM.NS's ROE is +0.26%, compared to ASTRAZEN.NS's ROE of +0.27%. Regarding short-term risk, AJANTPHARM.NS is more volatile compared to ASTRAZEN.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AJANTPHARM.NS.Check ASTRAZEN.NS's competition here

AJANTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AJANTPHARM.NS stands at 372.2B. In comparison, PPLPHARMA.BO has a market cap of 214.6B. Regarding current trading prices, AJANTPHARM.NS is priced at ₹2,978.90, while PPLPHARMA.BO trades at ₹162.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AJANTPHARM.NS currently has a P/E ratio of 36.65, whereas PPLPHARMA.BO's P/E ratio is -130.77. In terms of profitability, AJANTPHARM.NS's ROE is +0.26%, compared to PPLPHARMA.BO's ROE of -0.02%. Regarding short-term risk, AJANTPHARM.NS is more volatile compared to PPLPHARMA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AJANTPHARM.NS.Check PPLPHARMA.BO's competition here

AJANTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AJANTPHARM.NS stands at 372.2B. In comparison, ERIS.BO has a market cap of 185.5B. Regarding current trading prices, AJANTPHARM.NS is priced at ₹2,978.90, while ERIS.BO trades at ₹1,361.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AJANTPHARM.NS currently has a P/E ratio of 36.65, whereas ERIS.BO's P/E ratio is 43.07. In terms of profitability, AJANTPHARM.NS's ROE is +0.26%, compared to ERIS.BO's ROE of +0.14%. Regarding short-term risk, AJANTPHARM.NS is more volatile compared to ERIS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AJANTPHARM.NS.Check ERIS.BO's competition here

AJANTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AJANTPHARM.NS stands at 372.2B. In comparison, ERIS.NS has a market cap of 185.4B. Regarding current trading prices, AJANTPHARM.NS is priced at ₹2,978.90, while ERIS.NS trades at ₹1,361.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AJANTPHARM.NS currently has a P/E ratio of 36.65, whereas ERIS.NS's P/E ratio is 43.11. In terms of profitability, AJANTPHARM.NS's ROE is +0.26%, compared to ERIS.NS's ROE of +0.14%. Regarding short-term risk, AJANTPHARM.NS is more volatile compared to ERIS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AJANTPHARM.NS.Check ERIS.NS's competition here

AJANTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AJANTPHARM.NS stands at 372.2B. In comparison, NATCOPHARM.NS has a market cap of 174.1B. Regarding current trading prices, AJANTPHARM.NS is priced at ₹2,978.90, while NATCOPHARM.NS trades at ₹972.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AJANTPHARM.NS currently has a P/E ratio of 36.65, whereas NATCOPHARM.NS's P/E ratio is 11.18. In terms of profitability, AJANTPHARM.NS's ROE is +0.26%, compared to NATCOPHARM.NS's ROE of +0.20%. Regarding short-term risk, AJANTPHARM.NS is less volatile compared to NATCOPHARM.NS. This indicates potentially lower risk in terms of short-term price fluctuations for AJANTPHARM.NS.Check NATCOPHARM.NS's competition here

AJANTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AJANTPHARM.NS stands at 372.2B. In comparison, NATCOPHARM.BO has a market cap of 174B. Regarding current trading prices, AJANTPHARM.NS is priced at ₹2,978.90, while NATCOPHARM.BO trades at ₹971.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AJANTPHARM.NS currently has a P/E ratio of 36.65, whereas NATCOPHARM.BO's P/E ratio is 11.31. In terms of profitability, AJANTPHARM.NS's ROE is +0.26%, compared to NATCOPHARM.BO's ROE of +0.20%. Regarding short-term risk, AJANTPHARM.NS is less volatile compared to NATCOPHARM.BO. This indicates potentially lower risk in terms of short-term price fluctuations for AJANTPHARM.NS.Check NATCOPHARM.BO's competition here

AJANTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AJANTPHARM.NS stands at 372.2B. In comparison, NEULANDLAB.BO has a market cap of 169.5B. Regarding current trading prices, AJANTPHARM.NS is priced at ₹2,978.90, while NEULANDLAB.BO trades at ₹13,211.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AJANTPHARM.NS currently has a P/E ratio of 36.65, whereas NEULANDLAB.BO's P/E ratio is 94.40. In terms of profitability, AJANTPHARM.NS's ROE is +0.26%, compared to NEULANDLAB.BO's ROE of +0.12%. Regarding short-term risk, AJANTPHARM.NS is less volatile compared to NEULANDLAB.BO. This indicates potentially lower risk in terms of short-term price fluctuations for AJANTPHARM.NS.Check NEULANDLAB.BO's competition here

AJANTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AJANTPHARM.NS stands at 372.2B. In comparison, NEULANDLAB.NS has a market cap of 169.4B. Regarding current trading prices, AJANTPHARM.NS is priced at ₹2,978.90, while NEULANDLAB.NS trades at ₹13,204.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AJANTPHARM.NS currently has a P/E ratio of 36.65, whereas NEULANDLAB.NS's P/E ratio is 94.83. In terms of profitability, AJANTPHARM.NS's ROE is +0.26%, compared to NEULANDLAB.NS's ROE of +0.12%. Regarding short-term risk, AJANTPHARM.NS is less volatile compared to NEULANDLAB.NS. This indicates potentially lower risk in terms of short-term price fluctuations for AJANTPHARM.NS.Check NEULANDLAB.NS's competition here

AJANTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AJANTPHARM.NS stands at 372.2B. In comparison, GRANULES.NS has a market cap of 143.4B. Regarding current trading prices, AJANTPHARM.NS is priced at ₹2,978.90, while GRANULES.NS trades at ₹591.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AJANTPHARM.NS currently has a P/E ratio of 36.65, whereas GRANULES.NS's P/E ratio is 26.28. In terms of profitability, AJANTPHARM.NS's ROE is +0.26%, compared to GRANULES.NS's ROE of +0.15%. Regarding short-term risk, AJANTPHARM.NS is more volatile compared to GRANULES.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AJANTPHARM.NS.Check GRANULES.NS's competition here

AJANTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AJANTPHARM.NS stands at 372.2B. In comparison, APLLTD.NS has a market cap of 143.4B. Regarding current trading prices, AJANTPHARM.NS is priced at ₹2,978.90, while APLLTD.NS trades at ₹729.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AJANTPHARM.NS currently has a P/E ratio of 36.65, whereas APLLTD.NS's P/E ratio is 22.74. In terms of profitability, AJANTPHARM.NS's ROE is +0.26%, compared to APLLTD.NS's ROE of +0.12%. Regarding short-term risk, AJANTPHARM.NS is less volatile compared to APLLTD.NS. This indicates potentially lower risk in terms of short-term price fluctuations for AJANTPHARM.NS.Check APLLTD.NS's competition here

AJANTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AJANTPHARM.NS stands at 372.2B. In comparison, APLLTD.BO has a market cap of 143.3B. Regarding current trading prices, AJANTPHARM.NS is priced at ₹2,978.90, while APLLTD.BO trades at ₹728.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AJANTPHARM.NS currently has a P/E ratio of 36.65, whereas APLLTD.BO's P/E ratio is 22.73. In terms of profitability, AJANTPHARM.NS's ROE is +0.26%, compared to APLLTD.BO's ROE of +0.12%. Regarding short-term risk, AJANTPHARM.NS is less volatile compared to APLLTD.BO. This indicates potentially lower risk in terms of short-term price fluctuations for AJANTPHARM.NS.Check APLLTD.BO's competition here

AJANTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AJANTPHARM.NS stands at 372.2B. In comparison, GRANULES.BO has a market cap of 143.2B. Regarding current trading prices, AJANTPHARM.NS is priced at ₹2,978.90, while GRANULES.BO trades at ₹590.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AJANTPHARM.NS currently has a P/E ratio of 36.65, whereas GRANULES.BO's P/E ratio is 26.25. In terms of profitability, AJANTPHARM.NS's ROE is +0.26%, compared to GRANULES.BO's ROE of +0.15%. Regarding short-term risk, AJANTPHARM.NS is more volatile compared to GRANULES.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AJANTPHARM.NS.Check GRANULES.BO's competition here

AJANTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AJANTPHARM.NS stands at 372.2B. In comparison, JUBLPHARMA.NS has a market cap of 139.8B. Regarding current trading prices, AJANTPHARM.NS is priced at ₹2,978.90, while JUBLPHARMA.NS trades at ₹882.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AJANTPHARM.NS currently has a P/E ratio of 36.65, whereas JUBLPHARMA.NS's P/E ratio is 32.39. In terms of profitability, AJANTPHARM.NS's ROE is +0.26%, compared to JUBLPHARMA.NS's ROE of +0.07%. Regarding short-term risk, AJANTPHARM.NS is less volatile compared to JUBLPHARMA.NS. This indicates potentially lower risk in terms of short-term price fluctuations for AJANTPHARM.NS.Check JUBLPHARMA.NS's competition here

AJANTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AJANTPHARM.NS stands at 372.2B. In comparison, JUBLPHARMA.BO has a market cap of 139.7B. Regarding current trading prices, AJANTPHARM.NS is priced at ₹2,978.90, while JUBLPHARMA.BO trades at ₹881.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AJANTPHARM.NS currently has a P/E ratio of 36.65, whereas JUBLPHARMA.BO's P/E ratio is 32.40. In terms of profitability, AJANTPHARM.NS's ROE is +0.26%, compared to JUBLPHARMA.BO's ROE of +0.07%. Regarding short-term risk, AJANTPHARM.NS is less volatile compared to JUBLPHARMA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for AJANTPHARM.NS.Check JUBLPHARMA.BO's competition here

AJANTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AJANTPHARM.NS stands at 372.2B. In comparison, GLS.NS has a market cap of 133.1B. Regarding current trading prices, AJANTPHARM.NS is priced at ₹2,978.90, while GLS.NS trades at ₹1,086.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AJANTPHARM.NS currently has a P/E ratio of 36.65, whereas GLS.NS's P/E ratio is 31.50. In terms of profitability, AJANTPHARM.NS's ROE is +0.26%, compared to GLS.NS's ROE of +0.09%. Regarding short-term risk, AJANTPHARM.NS is less volatile compared to GLS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for AJANTPHARM.NS.Check GLS.NS's competition here

AJANTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AJANTPHARM.NS stands at 372.2B. In comparison, GLS.BO has a market cap of 133B. Regarding current trading prices, AJANTPHARM.NS is priced at ₹2,978.90, while GLS.BO trades at ₹1,085.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AJANTPHARM.NS currently has a P/E ratio of 36.65, whereas GLS.BO's P/E ratio is 30.23. In terms of profitability, AJANTPHARM.NS's ROE is +0.26%, compared to GLS.BO's ROE of +0.19%. Regarding short-term risk, AJANTPHARM.NS is less volatile compared to GLS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for AJANTPHARM.NS.Check GLS.BO's competition here

AJANTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AJANTPHARM.NS stands at 372.2B. In comparison, CAPLIPOINT.NS has a market cap of 131.4B. Regarding current trading prices, AJANTPHARM.NS is priced at ₹2,978.90, while CAPLIPOINT.NS trades at ₹1,728.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AJANTPHARM.NS currently has a P/E ratio of 36.65, whereas CAPLIPOINT.NS's P/E ratio is 21.49. In terms of profitability, AJANTPHARM.NS's ROE is +0.26%, compared to CAPLIPOINT.NS's ROE of +0.21%. Regarding short-term risk, AJANTPHARM.NS is more volatile compared to CAPLIPOINT.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AJANTPHARM.NS.Check CAPLIPOINT.NS's competition here

AJANTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AJANTPHARM.NS stands at 372.2B. In comparison, CAPLIPOINT.BO has a market cap of 131.2B. Regarding current trading prices, AJANTPHARM.NS is priced at ₹2,978.90, while CAPLIPOINT.BO trades at ₹1,726.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AJANTPHARM.NS currently has a P/E ratio of 36.65, whereas CAPLIPOINT.BO's P/E ratio is 21.42. In terms of profitability, AJANTPHARM.NS's ROE is +0.26%, compared to CAPLIPOINT.BO's ROE of +0.10%. Regarding short-term risk, AJANTPHARM.NS is more volatile compared to CAPLIPOINT.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AJANTPHARM.NS.Check CAPLIPOINT.BO's competition here

AJANTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AJANTPHARM.NS stands at 372.2B. In comparison, COHANCE.NS has a market cap of 118B. Regarding current trading prices, AJANTPHARM.NS is priced at ₹2,978.90, while COHANCE.NS trades at ₹308.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AJANTPHARM.NS currently has a P/E ratio of 36.65, whereas COHANCE.NS's P/E ratio is 61.06. In terms of profitability, AJANTPHARM.NS's ROE is +0.26%, compared to COHANCE.NS's ROE of +0.09%. Regarding short-term risk, AJANTPHARM.NS is less volatile compared to COHANCE.NS. This indicates potentially lower risk in terms of short-term price fluctuations for AJANTPHARM.NS.Check COHANCE.NS's competition here

AJANTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AJANTPHARM.NS stands at 372.2B. In comparison, COHANCE.BO has a market cap of 117.9B. Regarding current trading prices, AJANTPHARM.NS is priced at ₹2,978.90, while COHANCE.BO trades at ₹308.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AJANTPHARM.NS currently has a P/E ratio of 36.65, whereas COHANCE.BO's P/E ratio is 60.78. In terms of profitability, AJANTPHARM.NS's ROE is +0.26%, compared to COHANCE.BO's ROE of +0.09%. Regarding short-term risk, AJANTPHARM.NS is less volatile compared to COHANCE.BO. This indicates potentially lower risk in terms of short-term price fluctuations for AJANTPHARM.NS.Check COHANCE.BO's competition here

AJANTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AJANTPHARM.NS stands at 372.2B. In comparison, ALIVUS.BO has a market cap of 112.9B. Regarding current trading prices, AJANTPHARM.NS is priced at ₹2,978.90, while ALIVUS.BO trades at ₹920.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AJANTPHARM.NS currently has a P/E ratio of 36.65, whereas ALIVUS.BO's P/E ratio is 20.80. In terms of profitability, AJANTPHARM.NS's ROE is +0.26%, compared to ALIVUS.BO's ROE of +0.09%. Regarding short-term risk, AJANTPHARM.NS is less volatile compared to ALIVUS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for AJANTPHARM.NS.Check ALIVUS.BO's competition here

AJANTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AJANTPHARM.NS stands at 372.2B. In comparison, ALIVUS.NS has a market cap of 112.9B. Regarding current trading prices, AJANTPHARM.NS is priced at ₹2,978.90, while ALIVUS.NS trades at ₹920.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AJANTPHARM.NS currently has a P/E ratio of 36.65, whereas ALIVUS.NS's P/E ratio is 20.79. In terms of profitability, AJANTPHARM.NS's ROE is +0.26%, compared to ALIVUS.NS's ROE of +0.19%. Regarding short-term risk, AJANTPHARM.NS is less volatile compared to ALIVUS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for AJANTPHARM.NS.Check ALIVUS.NS's competition here

AJANTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AJANTPHARM.NS stands at 372.2B. In comparison, CAPPL.BO has a market cap of 109.4B. Regarding current trading prices, AJANTPHARM.NS is priced at ₹2,978.90, while CAPPL.BO trades at ₹1,446.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AJANTPHARM.NS currently has a P/E ratio of 36.65, whereas CAPPL.BO's P/E ratio is 50.30. In terms of profitability, AJANTPHARM.NS's ROE is +0.26%, compared to CAPPL.BO's ROE of +0.10%. Regarding short-term risk, AJANTPHARM.NS is less volatile compared to CAPPL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for AJANTPHARM.NS.Check CAPPL.BO's competition here

AJANTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AJANTPHARM.NS stands at 372.2B. In comparison, VIYASH.NS has a market cap of 98.4B. Regarding current trading prices, AJANTPHARM.NS is priced at ₹2,978.90, while VIYASH.NS trades at ₹225.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AJANTPHARM.NS currently has a P/E ratio of 36.65, whereas VIYASH.NS's P/E ratio is 87.06. In terms of profitability, AJANTPHARM.NS's ROE is +0.26%, compared to VIYASH.NS's ROE of +0.10%. Regarding short-term risk, AJANTPHARM.NS is less volatile compared to VIYASH.NS. This indicates potentially lower risk in terms of short-term price fluctuations for AJANTPHARM.NS.Check VIYASH.NS's competition here

AJANTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AJANTPHARM.NS stands at 372.2B. In comparison, PGHL.BO has a market cap of 85.1B. Regarding current trading prices, AJANTPHARM.NS is priced at ₹2,978.90, while PGHL.BO trades at ₹5,128.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AJANTPHARM.NS currently has a P/E ratio of 36.65, whereas PGHL.BO's P/E ratio is 36.01. In terms of profitability, AJANTPHARM.NS's ROE is +0.26%, compared to PGHL.BO's ROE of +0.51%. Regarding short-term risk, AJANTPHARM.NS is more volatile compared to PGHL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AJANTPHARM.NS.Check PGHL.BO's competition here

AJANTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AJANTPHARM.NS stands at 372.2B. In comparison, PGHL.NS has a market cap of 85.1B. Regarding current trading prices, AJANTPHARM.NS is priced at ₹2,978.90, while PGHL.NS trades at ₹5,124.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AJANTPHARM.NS currently has a P/E ratio of 36.65, whereas PGHL.NS's P/E ratio is 35.97. In terms of profitability, AJANTPHARM.NS's ROE is +0.26%, compared to PGHL.NS's ROE of +0.51%. Regarding short-term risk, AJANTPHARM.NS is more volatile compared to PGHL.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AJANTPHARM.NS.Check PGHL.NS's competition here

AJANTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AJANTPHARM.NS stands at 372.2B. In comparison, STAR.NS has a market cap of 79.6B. Regarding current trading prices, AJANTPHARM.NS is priced at ₹2,978.90, while STAR.NS trades at ₹863.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AJANTPHARM.NS currently has a P/E ratio of 36.65, whereas STAR.NS's P/E ratio is 15.57. In terms of profitability, AJANTPHARM.NS's ROE is +0.26%, compared to STAR.NS's ROE of +0.20%. Regarding short-term risk, AJANTPHARM.NS is more volatile compared to STAR.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AJANTPHARM.NS.Check STAR.NS's competition here

AJANTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AJANTPHARM.NS stands at 372.2B. In comparison, STAR.BO has a market cap of 79.5B. Regarding current trading prices, AJANTPHARM.NS is priced at ₹2,978.90, while STAR.BO trades at ₹862.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AJANTPHARM.NS currently has a P/E ratio of 36.65, whereas STAR.BO's P/E ratio is 15.55. In terms of profitability, AJANTPHARM.NS's ROE is +0.26%, compared to STAR.BO's ROE of +0.20%. Regarding short-term risk, AJANTPHARM.NS is more volatile compared to STAR.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AJANTPHARM.NS.Check STAR.BO's competition here

AJANTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AJANTPHARM.NS stands at 372.2B. In comparison, AKUMS.NS has a market cap of 73.8B. Regarding current trading prices, AJANTPHARM.NS is priced at ₹2,978.90, while AKUMS.NS trades at ₹482.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AJANTPHARM.NS currently has a P/E ratio of 36.65, whereas AKUMS.NS's P/E ratio is 23.05. In terms of profitability, AJANTPHARM.NS's ROE is +0.26%, compared to AKUMS.NS's ROE of +0.11%. Regarding short-term risk, AJANTPHARM.NS is more volatile compared to AKUMS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AJANTPHARM.NS.Check AKUMS.NS's competition here

AJANTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AJANTPHARM.NS stands at 372.2B. In comparison, SHILPAMED.NS has a market cap of 66.4B. Regarding current trading prices, AJANTPHARM.NS is priced at ₹2,978.90, while SHILPAMED.NS trades at ₹339.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AJANTPHARM.NS currently has a P/E ratio of 36.65, whereas SHILPAMED.NS's P/E ratio is 30.01. In terms of profitability, AJANTPHARM.NS's ROE is +0.26%, compared to SHILPAMED.NS's ROE of +0.06%. Regarding short-term risk, AJANTPHARM.NS is less volatile compared to SHILPAMED.NS. This indicates potentially lower risk in terms of short-term price fluctuations for AJANTPHARM.NS.Check SHILPAMED.NS's competition here

AJANTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AJANTPHARM.NS stands at 372.2B. In comparison, AARTIPHARM.NS has a market cap of 65.2B. Regarding current trading prices, AJANTPHARM.NS is priced at ₹2,978.90, while AARTIPHARM.NS trades at ₹719.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AJANTPHARM.NS currently has a P/E ratio of 36.65, whereas AARTIPHARM.NS's P/E ratio is 30.55. In terms of profitability, AJANTPHARM.NS's ROE is +0.26%, compared to AARTIPHARM.NS's ROE of +0.11%. Regarding short-term risk, AJANTPHARM.NS is less volatile compared to AARTIPHARM.NS. This indicates potentially lower risk in terms of short-term price fluctuations for AJANTPHARM.NS.Check AARTIPHARM.NS's competition here

AJANTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AJANTPHARM.NS stands at 372.2B. In comparison, AARTIPHARM.BO has a market cap of 65.1B. Regarding current trading prices, AJANTPHARM.NS is priced at ₹2,978.90, while AARTIPHARM.BO trades at ₹717.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AJANTPHARM.NS currently has a P/E ratio of 36.65, whereas AARTIPHARM.BO's P/E ratio is 30.51. In terms of profitability, AJANTPHARM.NS's ROE is +0.26%, compared to AARTIPHARM.BO's ROE of +0.11%. Regarding short-term risk, AJANTPHARM.NS is less volatile compared to AARTIPHARM.BO. This indicates potentially lower risk in terms of short-term price fluctuations for AJANTPHARM.NS.Check AARTIPHARM.BO's competition here

AJANTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AJANTPHARM.NS stands at 372.2B. In comparison, FDC.BO has a market cap of 59.4B. Regarding current trading prices, AJANTPHARM.NS is priced at ₹2,978.90, while FDC.BO trades at ₹364.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AJANTPHARM.NS currently has a P/E ratio of 36.65, whereas FDC.BO's P/E ratio is 27.46. In terms of profitability, AJANTPHARM.NS's ROE is +0.26%, compared to FDC.BO's ROE of +0.09%. Regarding short-term risk, AJANTPHARM.NS is more volatile compared to FDC.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AJANTPHARM.NS.Check FDC.BO's competition here

AJANTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AJANTPHARM.NS stands at 372.2B. In comparison, FDC.NS has a market cap of 59.1B. Regarding current trading prices, AJANTPHARM.NS is priced at ₹2,978.90, while FDC.NS trades at ₹363.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AJANTPHARM.NS currently has a P/E ratio of 36.65, whereas FDC.NS's P/E ratio is 27.35. In terms of profitability, AJANTPHARM.NS's ROE is +0.26%, compared to FDC.NS's ROE of +0.09%. Regarding short-term risk, AJANTPHARM.NS is more volatile compared to FDC.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AJANTPHARM.NS.Check FDC.NS's competition here

AJANTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AJANTPHARM.NS stands at 372.2B. In comparison, SEQUENT.NS has a market cap of 50.6B. Regarding current trading prices, AJANTPHARM.NS is priced at ₹2,978.90, while SEQUENT.NS trades at ₹202.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AJANTPHARM.NS currently has a P/E ratio of 36.65, whereas SEQUENT.NS's P/E ratio is 124.17. In terms of profitability, AJANTPHARM.NS's ROE is +0.26%, compared to SEQUENT.NS's ROE of +0.06%. Regarding short-term risk, AJANTPHARM.NS is less volatile compared to SEQUENT.NS. This indicates potentially lower risk in terms of short-term price fluctuations for AJANTPHARM.NS.Check SEQUENT.NS's competition here

AJANTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AJANTPHARM.NS stands at 372.2B. In comparison, SEQUENT.BO has a market cap of 50.6B. Regarding current trading prices, AJANTPHARM.NS is priced at ₹2,978.90, while SEQUENT.BO trades at ₹202.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AJANTPHARM.NS currently has a P/E ratio of 36.65, whereas SEQUENT.BO's P/E ratio is 123.41. In terms of profitability, AJANTPHARM.NS's ROE is +0.26%, compared to SEQUENT.BO's ROE of +0.10%. Regarding short-term risk, AJANTPHARM.NS is less volatile compared to SEQUENT.BO. This indicates potentially lower risk in terms of short-term price fluctuations for AJANTPHARM.NS.Check SEQUENT.BO's competition here

AJANTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AJANTPHARM.NS stands at 372.2B. In comparison, SPARC.NS has a market cap of 41.7B. Regarding current trading prices, AJANTPHARM.NS is priced at ₹2,978.90, while SPARC.NS trades at ₹128.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AJANTPHARM.NS currently has a P/E ratio of 36.65, whereas SPARC.NS's P/E ratio is -15.57. In terms of profitability, AJANTPHARM.NS's ROE is +0.26%, compared to SPARC.NS's ROE of +1.25%. Regarding short-term risk, AJANTPHARM.NS is more volatile compared to SPARC.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AJANTPHARM.NS.Check SPARC.NS's competition here

AJANTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AJANTPHARM.NS stands at 372.2B. In comparison, SPARC.BO has a market cap of 41.6B. Regarding current trading prices, AJANTPHARM.NS is priced at ₹2,978.90, while SPARC.BO trades at ₹128.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AJANTPHARM.NS currently has a P/E ratio of 36.65, whereas SPARC.BO's P/E ratio is -15.53. In terms of profitability, AJANTPHARM.NS's ROE is +0.26%, compared to SPARC.BO's ROE of +1.25%. Regarding short-term risk, AJANTPHARM.NS is more volatile compared to SPARC.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AJANTPHARM.NS.Check SPARC.BO's competition here

AJANTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AJANTPHARM.NS stands at 372.2B. In comparison, INNOVACAP.NS has a market cap of 38.5B. Regarding current trading prices, AJANTPHARM.NS is priced at ₹2,978.90, while INNOVACAP.NS trades at ₹673.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AJANTPHARM.NS currently has a P/E ratio of 36.65, whereas INNOVACAP.NS's P/E ratio is 29.13. In terms of profitability, AJANTPHARM.NS's ROE is +0.26%, compared to INNOVACAP.NS's ROE of +0.14%. Regarding short-term risk, AJANTPHARM.NS is more volatile compared to INNOVACAP.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AJANTPHARM.NS.Check INNOVACAP.NS's competition here

AJANTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AJANTPHARM.NS stands at 372.2B. In comparison, GUJTHEM.NS has a market cap of 34.1B. Regarding current trading prices, AJANTPHARM.NS is priced at ₹2,978.90, while GUJTHEM.NS trades at ₹313.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AJANTPHARM.NS currently has a P/E ratio of 36.65, whereas GUJTHEM.NS's P/E ratio is 71.18. In terms of profitability, AJANTPHARM.NS's ROE is +0.26%, compared to GUJTHEM.NS's ROE of +0.19%. Regarding short-term risk, AJANTPHARM.NS is more volatile compared to GUJTHEM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AJANTPHARM.NS.Check GUJTHEM.NS's competition here

AJANTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AJANTPHARM.NS stands at 372.2B. In comparison, AARTIDRUGS.NS has a market cap of 33.7B. Regarding current trading prices, AJANTPHARM.NS is priced at ₹2,978.90, while AARTIDRUGS.NS trades at ₹369.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AJANTPHARM.NS currently has a P/E ratio of 36.65, whereas AARTIDRUGS.NS's P/E ratio is 16.72. In terms of profitability, AJANTPHARM.NS's ROE is +0.26%, compared to AARTIDRUGS.NS's ROE of +0.15%. Regarding short-term risk, AJANTPHARM.NS is more volatile compared to AARTIDRUGS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AJANTPHARM.NS.Check AARTIDRUGS.NS's competition here

AJANTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AJANTPHARM.NS stands at 372.2B. In comparison, SUVEN.BO has a market cap of 33.7B. Regarding current trading prices, AJANTPHARM.NS is priced at ₹2,978.90, while SUVEN.BO trades at ₹148.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AJANTPHARM.NS currently has a P/E ratio of 36.65, whereas SUVEN.BO's P/E ratio is -12.03. In terms of profitability, AJANTPHARM.NS's ROE is +0.26%, compared to SUVEN.BO's ROE of -1.58%. Regarding short-term risk, AJANTPHARM.NS is less volatile compared to SUVEN.BO. This indicates potentially lower risk in terms of short-term price fluctuations for AJANTPHARM.NS.Check SUVEN.BO's competition here

AJANTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AJANTPHARM.NS stands at 372.2B. In comparison, AARTIDRUGS.BO has a market cap of 33.6B. Regarding current trading prices, AJANTPHARM.NS is priced at ₹2,978.90, while AARTIDRUGS.BO trades at ₹368.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AJANTPHARM.NS currently has a P/E ratio of 36.65, whereas AARTIDRUGS.BO's P/E ratio is 16.67. In terms of profitability, AJANTPHARM.NS's ROE is +0.26%, compared to AARTIDRUGS.BO's ROE of +0.15%. Regarding short-term risk, AJANTPHARM.NS is more volatile compared to AARTIDRUGS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AJANTPHARM.NS.Check AARTIDRUGS.BO's competition here

AJANTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AJANTPHARM.NS stands at 372.2B. In comparison, SUVEN.NS has a market cap of 33.5B. Regarding current trading prices, AJANTPHARM.NS is priced at ₹2,978.90, while SUVEN.NS trades at ₹147.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AJANTPHARM.NS currently has a P/E ratio of 36.65, whereas SUVEN.NS's P/E ratio is -11.94. In terms of profitability, AJANTPHARM.NS's ROE is +0.26%, compared to SUVEN.NS's ROE of -1.58%. Regarding short-term risk, AJANTPHARM.NS is less volatile compared to SUVEN.NS. This indicates potentially lower risk in terms of short-term price fluctuations for AJANTPHARM.NS.Check SUVEN.NS's competition here

AJANTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AJANTPHARM.NS stands at 372.2B. In comparison, SHILPAMED.BO has a market cap of 33.3B. Regarding current trading prices, AJANTPHARM.NS is priced at ₹2,978.90, while SHILPAMED.BO trades at ₹340.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AJANTPHARM.NS currently has a P/E ratio of 36.65, whereas SHILPAMED.BO's P/E ratio is 30.16. In terms of profitability, AJANTPHARM.NS's ROE is +0.26%, compared to SHILPAMED.BO's ROE of +0.06%. Regarding short-term risk, AJANTPHARM.NS is less volatile compared to SHILPAMED.BO. This indicates potentially lower risk in terms of short-term price fluctuations for AJANTPHARM.NS.Check SHILPAMED.BO's competition here

AJANTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AJANTPHARM.NS stands at 372.2B. In comparison, ORCHPHARMA.BO has a market cap of 31.9B. Regarding current trading prices, AJANTPHARM.NS is priced at ₹2,978.90, while ORCHPHARMA.BO trades at ₹629.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AJANTPHARM.NS currently has a P/E ratio of 36.65, whereas ORCHPHARMA.BO's P/E ratio is 167.83. In terms of profitability, AJANTPHARM.NS's ROE is +0.26%, compared to ORCHPHARMA.BO's ROE of +0.00%. Regarding short-term risk, AJANTPHARM.NS is less volatile compared to ORCHPHARMA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for AJANTPHARM.NS.Check ORCHPHARMA.BO's competition here

AJANTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AJANTPHARM.NS stands at 372.2B. In comparison, ORCHPHARMA.NS has a market cap of 31.8B. Regarding current trading prices, AJANTPHARM.NS is priced at ₹2,978.90, while ORCHPHARMA.NS trades at ₹627.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AJANTPHARM.NS currently has a P/E ratio of 36.65, whereas ORCHPHARMA.NS's P/E ratio is 168.24. In terms of profitability, AJANTPHARM.NS's ROE is +0.26%, compared to ORCHPHARMA.NS's ROE of +0.01%. Regarding short-term risk, AJANTPHARM.NS is less volatile compared to ORCHPHARMA.NS. This indicates potentially lower risk in terms of short-term price fluctuations for AJANTPHARM.NS.Check ORCHPHARMA.NS's competition here

AJANTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AJANTPHARM.NS stands at 372.2B. In comparison, RPGLIFE.BO has a market cap of 31.6B. Regarding current trading prices, AJANTPHARM.NS is priced at ₹2,978.90, while RPGLIFE.BO trades at ₹1,910.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AJANTPHARM.NS currently has a P/E ratio of 36.65, whereas RPGLIFE.BO's P/E ratio is 15.60. In terms of profitability, AJANTPHARM.NS's ROE is +0.26%, compared to RPGLIFE.BO's ROE of +0.41%. Regarding short-term risk, AJANTPHARM.NS is more volatile compared to RPGLIFE.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AJANTPHARM.NS.Check RPGLIFE.BO's competition here

AJANTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AJANTPHARM.NS stands at 372.2B. In comparison, RPGLIFE.NS has a market cap of 31.6B. Regarding current trading prices, AJANTPHARM.NS is priced at ₹2,978.90, while RPGLIFE.NS trades at ₹1,909.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AJANTPHARM.NS currently has a P/E ratio of 36.65, whereas RPGLIFE.NS's P/E ratio is 15.58. In terms of profitability, AJANTPHARM.NS's ROE is +0.26%, compared to RPGLIFE.NS's ROE of +0.41%. Regarding short-term risk, AJANTPHARM.NS is less volatile compared to RPGLIFE.NS. This indicates potentially lower risk in terms of short-term price fluctuations for AJANTPHARM.NS.Check RPGLIFE.NS's competition here

AJANTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AJANTPHARM.NS stands at 372.2B. In comparison, GUFICBIO.BO has a market cap of 28.4B. Regarding current trading prices, AJANTPHARM.NS is priced at ₹2,978.90, while GUFICBIO.BO trades at ₹283.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AJANTPHARM.NS currently has a P/E ratio of 36.65, whereas GUFICBIO.BO's P/E ratio is 50.09. In terms of profitability, AJANTPHARM.NS's ROE is +0.26%, compared to GUFICBIO.BO's ROE of +0.08%. Regarding short-term risk, AJANTPHARM.NS is less volatile compared to GUFICBIO.BO. This indicates potentially lower risk in terms of short-term price fluctuations for AJANTPHARM.NS.Check GUFICBIO.BO's competition here

AJANTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AJANTPHARM.NS stands at 372.2B. In comparison, GUFICBIO.NS has a market cap of 28.3B. Regarding current trading prices, AJANTPHARM.NS is priced at ₹2,978.90, while GUFICBIO.NS trades at ₹282.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AJANTPHARM.NS currently has a P/E ratio of 36.65, whereas GUFICBIO.NS's P/E ratio is 49.65. In terms of profitability, AJANTPHARM.NS's ROE is +0.26%, compared to GUFICBIO.NS's ROE of +0.08%. Regarding short-term risk, AJANTPHARM.NS is less volatile compared to GUFICBIO.NS. This indicates potentially lower risk in terms of short-term price fluctuations for AJANTPHARM.NS.Check GUFICBIO.NS's competition here

AJANTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AJANTPHARM.NS stands at 372.2B. In comparison, HIKAL.BO has a market cap of 24.9B. Regarding current trading prices, AJANTPHARM.NS is priced at ₹2,978.90, while HIKAL.BO trades at ₹202.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AJANTPHARM.NS currently has a P/E ratio of 36.65, whereas HIKAL.BO's P/E ratio is 252.56. In terms of profitability, AJANTPHARM.NS's ROE is +0.26%, compared to HIKAL.BO's ROE of -0.01%. Regarding short-term risk, AJANTPHARM.NS is less volatile compared to HIKAL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for AJANTPHARM.NS.Check HIKAL.BO's competition here

AJANTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AJANTPHARM.NS stands at 372.2B. In comparison, HIKAL.NS has a market cap of 24.8B. Regarding current trading prices, AJANTPHARM.NS is priced at ₹2,978.90, while HIKAL.NS trades at ₹201.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AJANTPHARM.NS currently has a P/E ratio of 36.65, whereas HIKAL.NS's P/E ratio is -190.11. In terms of profitability, AJANTPHARM.NS's ROE is +0.26%, compared to HIKAL.NS's ROE of -0.01%. Regarding short-term risk, AJANTPHARM.NS is less volatile compared to HIKAL.NS. This indicates potentially lower risk in terms of short-term price fluctuations for AJANTPHARM.NS.Check HIKAL.NS's competition here

AJANTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AJANTPHARM.NS stands at 372.2B. In comparison, UNICHEMLAB.BO has a market cap of 24.8B. Regarding current trading prices, AJANTPHARM.NS is priced at ₹2,978.90, while UNICHEMLAB.BO trades at ₹352.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AJANTPHARM.NS currently has a P/E ratio of 36.65, whereas UNICHEMLAB.BO's P/E ratio is 8.44. In terms of profitability, AJANTPHARM.NS's ROE is +0.26%, compared to UNICHEMLAB.BO's ROE of +0.12%. Regarding short-term risk, AJANTPHARM.NS is less volatile compared to UNICHEMLAB.BO. This indicates potentially lower risk in terms of short-term price fluctuations for AJANTPHARM.NS.Check UNICHEMLAB.BO's competition here

AJANTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AJANTPHARM.NS stands at 372.2B. In comparison, UNICHEMLAB.NS has a market cap of 24.7B. Regarding current trading prices, AJANTPHARM.NS is priced at ₹2,978.90, while UNICHEMLAB.NS trades at ₹350.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AJANTPHARM.NS currently has a P/E ratio of 36.65, whereas UNICHEMLAB.NS's P/E ratio is 8.39. In terms of profitability, AJANTPHARM.NS's ROE is +0.26%, compared to UNICHEMLAB.NS's ROE of +0.12%. Regarding short-term risk, AJANTPHARM.NS is less volatile compared to UNICHEMLAB.NS. This indicates potentially lower risk in terms of short-term price fluctuations for AJANTPHARM.NS.Check UNICHEMLAB.NS's competition here

AJANTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AJANTPHARM.NS stands at 372.2B. In comparison, MOREPENLAB.BO has a market cap of 24.5B. Regarding current trading prices, AJANTPHARM.NS is priced at ₹2,978.90, while MOREPENLAB.BO trades at ₹44.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AJANTPHARM.NS currently has a P/E ratio of 36.65, whereas MOREPENLAB.BO's P/E ratio is 24.97. In terms of profitability, AJANTPHARM.NS's ROE is +0.26%, compared to MOREPENLAB.BO's ROE of +0.09%. Regarding short-term risk, AJANTPHARM.NS is less volatile compared to MOREPENLAB.BO. This indicates potentially lower risk in terms of short-term price fluctuations for AJANTPHARM.NS.Check MOREPENLAB.BO's competition here

AJANTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AJANTPHARM.NS stands at 372.2B. In comparison, MOREPENLAB.NS has a market cap of 24.5B. Regarding current trading prices, AJANTPHARM.NS is priced at ₹2,978.90, while MOREPENLAB.NS trades at ₹44.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AJANTPHARM.NS currently has a P/E ratio of 36.65, whereas MOREPENLAB.NS's P/E ratio is 24.81. In terms of profitability, AJANTPHARM.NS's ROE is +0.26%, compared to MOREPENLAB.NS's ROE of +0.09%. Regarding short-term risk, AJANTPHARM.NS is less volatile compared to MOREPENLAB.NS. This indicates potentially lower risk in terms of short-term price fluctuations for AJANTPHARM.NS.Check MOREPENLAB.NS's competition here

AJANTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AJANTPHARM.NS stands at 372.2B. In comparison, ALEMBICLTD.NS has a market cap of 23.4B. Regarding current trading prices, AJANTPHARM.NS is priced at ₹2,978.90, while ALEMBICLTD.NS trades at ₹91.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AJANTPHARM.NS currently has a P/E ratio of 36.65, whereas ALEMBICLTD.NS's P/E ratio is 7.23. In terms of profitability, AJANTPHARM.NS's ROE is +0.26%, compared to ALEMBICLTD.NS's ROE of +0.13%. Regarding short-term risk, AJANTPHARM.NS is less volatile compared to ALEMBICLTD.NS. This indicates potentially lower risk in terms of short-term price fluctuations for AJANTPHARM.NS.Check ALEMBICLTD.NS's competition here

AJANTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AJANTPHARM.NS stands at 372.2B. In comparison, BLISSGVS.BO has a market cap of 23B. Regarding current trading prices, AJANTPHARM.NS is priced at ₹2,978.90, while BLISSGVS.BO trades at ₹217.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AJANTPHARM.NS currently has a P/E ratio of 36.65, whereas BLISSGVS.BO's P/E ratio is 21.37. In terms of profitability, AJANTPHARM.NS's ROE is +0.26%, compared to BLISSGVS.BO's ROE of +0.10%. Regarding short-term risk, AJANTPHARM.NS is less volatile compared to BLISSGVS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for AJANTPHARM.NS.Check BLISSGVS.BO's competition here

AJANTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AJANTPHARM.NS stands at 372.2B. In comparison, BLISSGVS.NS has a market cap of 23B. Regarding current trading prices, AJANTPHARM.NS is priced at ₹2,978.90, while BLISSGVS.NS trades at ₹217.37.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AJANTPHARM.NS currently has a P/E ratio of 36.65, whereas BLISSGVS.NS's P/E ratio is 21.37. In terms of profitability, AJANTPHARM.NS's ROE is +0.26%, compared to BLISSGVS.NS's ROE of +0.10%. Regarding short-term risk, AJANTPHARM.NS is less volatile compared to BLISSGVS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for AJANTPHARM.NS.Check BLISSGVS.NS's competition here

AJANTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AJANTPHARM.NS stands at 372.2B. In comparison, NOVARTIND.BO has a market cap of 22.8B. Regarding current trading prices, AJANTPHARM.NS is priced at ₹2,978.90, while NOVARTIND.BO trades at ₹924.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AJANTPHARM.NS currently has a P/E ratio of 36.65, whereas NOVARTIND.BO's P/E ratio is 23.50. In terms of profitability, AJANTPHARM.NS's ROE is +0.26%, compared to NOVARTIND.BO's ROE of +0.13%. Regarding short-term risk, AJANTPHARM.NS is less volatile compared to NOVARTIND.BO. This indicates potentially lower risk in terms of short-term price fluctuations for AJANTPHARM.NS.Check NOVARTIND.BO's competition here

AJANTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AJANTPHARM.NS stands at 372.2B. In comparison, SOLARA.BO has a market cap of 22.3B. Regarding current trading prices, AJANTPHARM.NS is priced at ₹2,978.90, while SOLARA.BO trades at ₹463.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AJANTPHARM.NS currently has a P/E ratio of 36.65, whereas SOLARA.BO's P/E ratio is -96.30. In terms of profitability, AJANTPHARM.NS's ROE is +0.26%, compared to SOLARA.BO's ROE of -0.02%. Regarding short-term risk, AJANTPHARM.NS is less volatile compared to SOLARA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for AJANTPHARM.NS.Check SOLARA.BO's competition here

AJANTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AJANTPHARM.NS stands at 372.2B. In comparison, SOLARA.NS has a market cap of 22.3B. Regarding current trading prices, AJANTPHARM.NS is priced at ₹2,978.90, while SOLARA.NS trades at ₹463.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AJANTPHARM.NS currently has a P/E ratio of 36.65, whereas SOLARA.NS's P/E ratio is -95.87. In terms of profitability, AJANTPHARM.NS's ROE is +0.26%, compared to SOLARA.NS's ROE of -0.02%. Regarding short-term risk, AJANTPHARM.NS is less volatile compared to SOLARA.NS. This indicates potentially lower risk in terms of short-term price fluctuations for AJANTPHARM.NS.Check SOLARA.NS's competition here

AJANTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AJANTPHARM.NS stands at 372.2B. In comparison, IOLCP.NS has a market cap of 21.7B. Regarding current trading prices, AJANTPHARM.NS is priced at ₹2,978.90, while IOLCP.NS trades at ₹74.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AJANTPHARM.NS currently has a P/E ratio of 36.65, whereas IOLCP.NS's P/E ratio is 18.74. In terms of profitability, AJANTPHARM.NS's ROE is +0.26%, compared to IOLCP.NS's ROE of +0.07%. Regarding short-term risk, AJANTPHARM.NS is less volatile compared to IOLCP.NS. This indicates potentially lower risk in terms of short-term price fluctuations for AJANTPHARM.NS.Check IOLCP.NS's competition here

AJANTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AJANTPHARM.NS stands at 372.2B. In comparison, IOLCP.BO has a market cap of 21.7B. Regarding current trading prices, AJANTPHARM.NS is priced at ₹2,978.90, while IOLCP.BO trades at ₹73.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AJANTPHARM.NS currently has a P/E ratio of 36.65, whereas IOLCP.BO's P/E ratio is 18.71. In terms of profitability, AJANTPHARM.NS's ROE is +0.26%, compared to IOLCP.BO's ROE of +0.07%. Regarding short-term risk, AJANTPHARM.NS is less volatile compared to IOLCP.BO. This indicates potentially lower risk in terms of short-term price fluctuations for AJANTPHARM.NS.Check IOLCP.BO's competition here